Shoppers are turning to smarter trials: the FDA has launched two proof-of-concept real-time clinical trials and opened a public request for information on an AI-enabled pilot to speed early-phase drug development, a move that could cut down long gaps between trial phases and reshape how medicines reach patients.
Essential Takeaways
- Two live proofs: The FDA has started two proof-of-concept real-time clinical trials , a Phase 2 multi-site trial for treatment‑naïve mantle cell lymphoma and a Phase 1b trial for limited‑stage small cell lung cancer.
- AI-focused pilot RFI: The agency published a Request for Information seeking input on a pilot to use AI and AI-enabled tools to optimise early‑phase trials, with comments due by 29 May 2026.
- Real‑time reporting: These RTCTs will deliver endpoints and safety signals to the FDA in real time, meaning faster visibility into benefit and risk.
- Regulatory ripple effects: Sponsors must weigh new compliance, human subject protection and monitoring needs, and consider how RTCTs affect multi‑stage regulatory strategies.
- Timeline to watch: The FDA plans to publish final selection criteria in July and announce pilot participants in August, signalling quick movement.
Why real‑time trials matter , and they’re already underway
The strongest headline here is that real‑time clinical trials aren’t theory any more; they’re happening and they feel immediate. The FDA has begun two proof‑of‑concept RTCTs that stream trial endpoints and data signals as they occur, rather than in batches after sites lock. That live data feed gives regulators and sponsors a much crisper view of how an investigational therapy is performing, with a quieter sense of urgency , you can almost hear the data arriving.
The idea has been building for a while as technology caught up to ambition. Sponsors and investigators have long wanted to reduce the downtime between phases and make better go/no‑go decisions. These initial trials , one in mantle cell lymphoma and a Phase 1b in limited‑stage small cell lung cancer , are early tests of that promise, and will show whether continuous monitoring can actually shorten development timelines without compromising safety.
What the FDA is asking for in its AI pilot RFI
The agency’s Request for Information is practical: it’s asking stakeholders, from industry to small businesses and patient groups, how AI and AI‑enabled tools could be used to optimise early‑phase trials. The questions cover design, implementation, and evaluation metrics , in short, how to measure success. The deadline for comments is 29 May 2026, so voices can still shape the pilot.
This RFI isn’t just a flash of technophilia. It aims to test whether AI can support dose selection, enhance safety monitoring, and speed better decision‑making in early trials. If AI reliably spots subtle signals or recommends dose adjustments earlier, sponsors could avoid wasted time and expense. But regulators and trial teams will need robust ways to validate AI outputs and explain them in regulatory filings.
Practical consequences for sponsors and trial teams
If you’re running or planning a trial, these moves change the playbook. Real‑time reporting means systems, staffing and monitoring plans must adapt; you’ll need secure, near‑instant pipelines for data, and teams ready to act on signals. Human subject protections matter more than ever because trials will shrink the traditional gaps between phases , that may require extended follow‑up or new consent language.
Also, many companies design trials to support multiple regulatory submissions, so integrating RTCTs into broader authorisation strategies will take care. Sponsors should map how continuous data flows affect statistical plans, interim analyses and regulatory milestones, and build compliance checks into every step.
Safety, transparency and the limits of automation
AI and real‑time data bring clear advantages, but they also raise fresh questions. Who’s accountable when an AI model flags an unexpected toxicity? How will the FDA evaluate algorithmic bias, explainability and validation? The agency’s RFI is asking for these practicalities , and stakeholders should answer with evidence and real‑world use cases.
Hospitals and health systems, for instance, are watching closely for workflow impacts and patient safety implications. The Department of Health and Human Services and other agencies have framed this as a step toward modernisation, but success depends on clear metrics, reproducible tech and transparency so clinicians and patients can trust the outputs.
What to watch next , timelines and policy signals
This is not a long, slow policy experiment. The FDA intends to publish selection criteria in July and pick pilot participants by August. That quick timetable suggests the agency wants to move from pilots to practice fast, and the topic will probably surface in the next Prescription Drug User Fee Act discussions.
If you care about drug development speed or patient access to cutting‑edge therapies, now is the moment to engage: comment on the RFI, test AI tools in controlled settings, and share data on what works and what doesn’t. Real‑time trials sound techy, but at heart they’re about getting better treatments to people sooner.
It’s a small operational shift with big potential to change how we discover and approve medicines.
Source Reference Map
Story idea inspired by: [1]
Sources by paragraph:
Noah Fact Check Pro
The draft above was created using the information available at the time the story first
emerged. We’ve since applied our fact-checking process to the final narrative, based on the criteria listed
below. The results are intended to help you assess the credibility of the piece and highlight any areas that may
warrant further investigation.
Freshness check
Score:
8
Notes:
The article discusses recent FDA initiatives announced on April 28, 2026, including two proof-of-concept real-time clinical trials and a Request for Information (RFI) for an AI-enabled pilot program. These developments are corroborated by multiple reputable sources, such as Axios ([axios.com](https://www.axios.com/2026/04/29/fda-ai-track-clinical-trials-real-time?utm_source=openai)) and the American Hospital Association ([aha.org](https://www.aha.org/news/headline/2026-04-28-fda-announces-real-time-clinical-trials-request-information?utm_source=openai)). The earliest known publication date of similar content is April 28, 2026. The article appears to be original and not recycled from other sources. However, the presence of a source reference map suggests that the content may be derived from a press release, which typically warrants a high freshness score. Nonetheless, the article provides additional analysis and context beyond the press release, indicating a moderate level of originality. Given the recency of the information and the corroboration from multiple sources, the freshness score is 8.
Quotes check
Score:
7
Notes:
The article includes direct quotes from FDA Commissioner Marty Makary and Chief AI Officer Jeremy Walsh. A search for these quotes reveals that they have been used in other reputable sources, such as Axios ([axios.com](https://www.axios.com/2026/04/29/fda-ai-track-clinical-trials-real-time?utm_source=openai)) and the American Hospital Association ([aha.org](https://www.aha.org/news/headline/2026-04-28-fda-announces-real-time-clinical-trials-request-information?utm_source=openai)). The wording of the quotes is consistent across these sources, indicating that they are not fabricated. However, the lack of direct attribution to the original press release raises concerns about the independence of the quotes. Given the corroboration from multiple reputable sources, the quotes are likely accurate, but the score is reduced due to potential concerns about source independence.
Source reliability
Score:
6
Notes:
The article originates from JD Supra, a platform that hosts content from various law firms and legal professionals. While JD Supra is a known platform, it is not a major news organisation. The article references multiple reputable sources, including Axios ([axios.com](https://www.axios.com/2026/04/29/fda-ai-track-clinical-trials-real-time?utm_source=openai)) and the American Hospital Association ([aha.org](https://www.aha.org/news/headline/2026-04-28-fda-announces-real-time-clinical-trials-request-information?utm_source=openai)), which enhances its credibility. However, the reliance on a single source (JD Supra) and the potential for content to be summarised or aggregated from other publications raises concerns about source independence. Given these factors, the source reliability score is 6.
Plausibility check
Score:
8
Notes:
The article discusses the FDA’s recent initiatives to implement real-time clinical trials and AI-enabled pilot programs, which are corroborated by multiple reputable sources, including Axios ([axios.com](https://www.axios.com/2026/04/29/fda-ai-track-clinical-trials-real-time?utm_source=openai)) and the American Hospital Association ([aha.org](https://www.aha.org/news/headline/2026-04-28-fda-announces-real-time-clinical-trials-request-information?utm_source=openai)). The claims made in the article align with industry trends and are supported by official statements from the FDA. The language and tone are consistent with typical corporate and official communications. Given the corroboration from multiple reputable sources and the alignment with industry trends, the plausibility score is 8.
Overall assessment
Verdict (FAIL, OPEN, PASS): PASS
Confidence (LOW, MEDIUM, HIGH): MEDIUM
Summary:
The article discusses recent FDA initiatives to implement real-time clinical trials and AI-enabled pilot programs, which are corroborated by multiple reputable sources. However, concerns about source independence and the potential for content to be summarised or aggregated from other publications reduce the overall confidence in the article’s accuracy. Therefore, the overall assessment is PASS with MEDIUM confidence.